Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.08), $0.33 better than the analyst estimate of ($1.41). Revenue for the quarter came in at $81.6 million versus the consensus estimate of $81.55 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Bending Spoons closes IPO, raises ~$954M on Nasdaq
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT